AtriCure (NASDAQ:ATRC) Releases FY 2026 Earnings Guidance

AtriCure (NASDAQ:ATRC) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.090-0.150 for the period, compared to the consensus earnings per share estimate of -0.030. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $604.3 million.

AtriCure Stock Performance

Shares of ATRC stock opened at $30.93 on Tuesday. The company has a market capitalization of $1.54 billion, a P/E ratio of -128.88 and a beta of 1.42. AtriCure has a fifty-two week low of $28.29 and a fifty-two week high of $43.18. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.99 and a current ratio of 3.96. The stock has a 50 day moving average price of $37.06 and a two-hundred day moving average price of $36.52.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Tuesday, February 17th. The medical device company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.10. AtriCure had a negative net margin of 2.14% and a negative return on equity of 1.15%. The firm had revenue of $140.50 million for the quarter, compared to analysts’ expectations of $140.50 million. During the same quarter last year, the business earned ($0.33) earnings per share. The business’s revenue was up 13.1% on a year-over-year basis. Analysts expect that AtriCure will post -0.6 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on ATRC shares. BTIG Research reaffirmed a “buy” rating and set a $54.00 price objective on shares of AtriCure in a research note on Wednesday, February 18th. Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. Citigroup reaffirmed an “outperform” rating on shares of AtriCure in a research report on Wednesday, February 18th. UBS Group cut their price objective on AtriCure from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, February 18th. Finally, Wall Street Zen upgraded AtriCure from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 21st. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.43.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. purchased a new stake in AtriCure in the second quarter worth $37,000. Smartleaf Asset Management LLC boosted its holdings in shares of AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after buying an additional 429 shares in the last quarter. State of Wyoming purchased a new stake in shares of AtriCure in the 4th quarter worth about $75,000. Kemnay Advisory Services Inc. purchased a new stake in shares of AtriCure in the 4th quarter worth about $114,000. Finally, Strs Ohio bought a new position in shares of AtriCure in the 1st quarter worth about $158,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.